Used in the treatment of multiple myeloma and other hematologic malignancies, Oprozomib is a proteasome inhibitor that disrupts protein degradation in cancer cells, leading to cell cycle arrest and apoptosis. It is being investigated in clinical trials for relapsed or refractory multiple myeloma due to its ability to overcome resistance to earlier-generation proteasome inhibitors like bortezomib. The compound shows improved pharmacokinetic properties and can be administered orally, offering a potential advantage in outpatient settings. Research also explores its efficacy in lymphomas and solid tumors, often in combination with other anticancer agents such as immunomodulatory drugs or dexamethasone.